Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: Formulation, pharmacokinetics, biodistribution and efficacy

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1085-1095

  Musende, Alain G ^a,b   Eberding, Andy ^a   Wood, Catherine ^a   Adomat, Hans ^a   Fazli, Ladan ^a   Hurtado Coll, Antonio ^a   Jia, William ^b,c   Bally, Marcel B ^b,d   Guns, Emma Tomlinson ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Biodistribution; Efficacy; Ginsenoside Rh2; Pharmacokinetics; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DOCETAXEL; GINSENOSIDE RH 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER MODEL; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 69049109763     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0965-1     Document Type: Article

References (37)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
2. R De Wit 2008 Chemotherapy in hormone-refractory prostate cancer BJU Int 101 Suppl 2 5 11
3. WK Oh 2003 The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer J Urol 170 S28 S32 discussion S33-4
4. MA Richardson T Sanders JL Palmer A Greisinger SE Singletary 2000 Complementary and alternative medicine use in a comprehensive cancer center and the implications for oncology J Clin Oncol 18 2505 2514
5. WW Jia X Bu D Philips H Yan G Liu X Chen JA Bush G Li 2004 Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy Can J Physiol Pharmacol 82 431 437
6. H Nakata Y Kikuchi T Tode J Hirata T Kita K Ishii K Kudoh I Nagata N Shinomiya 1998 Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells Jpn J Cancer Res 89 733 740
7. C Wakabayashi H Hasegawa J Murata I Saiki 1997 In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration Oncol Res 9 411 417
8. M Oh YH Choi S Choi H Chung K Kim SI Kim DK Kim ND Kim 1999 Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells Int J Oncol 14 869 875
9. W Wang H Wang ER Rayburn Y Zhao DL Hill R Zhang 2008 20(S)-25-methoxyl- dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action Br J Cancer 98 792 802
10. X Xie A Eberding C Madera L Fazli W Jia L Goldenberg M Gleave ES Guns 2006 Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models J Urol 175 1926 1931
11. SR Dunn Z Qi EP Bottinger MD Breyer K Sharma 2004 Utility of endogenous creatinine clearance as a measure of renal function in mice Kidney Int 65 1959 1967
12. J Wang G Zhou C Chen H Yu T Wang Y Ma G Jia Y Gao B Li J Sun Y Li F Jiao Y Zhao Z Chai 2007 Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration Toxicol Lett 168 176 185
13. K Kameyama H Takami S Umemura YR Osamura N Wada K Sugino T Mimura K Ito 2000 PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas Ann Surg Oncol 7 301 304
14. A Eberding C Madera S Xie CA Wood PN Brown ES Guns 2007 Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel Nutr Cancer 58 188 196
15. JC Low KM Wasan L Fazli A Eberding H Adomat ES Guns 2007 Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts Cancer Chemother Pharmacol 60 821 829
16. DH Shevrin KI Gorny SC Kukreja 1989 Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice Prostate 15 187 194
17. Y Wang JG Corr HT Thaler Y Tao WR Fair WD Heston 1995 Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet J Natl Cancer Inst 87 1456 1462
18. K Asgari IA Sesterhenn DG McLeod K Cowan JW Moul P Seth S Srivastava 1997 Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector Int J Cancer 71 377 382
19. T O'Reilly PM McSheehy F Wenger M Hattenberger M Muller J Vaxelaire KH Altmann M Wartmann 2005 Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo Prostate 65 231 240
20. GX Li HJ Lee Z Wang H Hu JD Liao JC Watts GF Combs Jr J Lu 2008 Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite Carcinogenesis 29 1005 1012
21. RA Newman J Yang M Raymond V Finlay F Cabral D Vourloumis LC Stephens P Troncoso X Wu CJ Logothetis KC Nicolaou NM Navone 2001 Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts Cancer Chemother Pharmacol 48 319 326
22. USP C (2000) USP Pharmacopeia & National Formulary. Board of Trustees of the USP Pharmacopeial Convention, Inc., Rockville, MD
23. DL Sorby RG Bitter JG Webb 1963 Dielectric constants of complex pharmaceutical solvent systems. I. Water-ethanol-glycerin and water-ethanol-propylene glycol J Pharm Sci 52 1149 1153
24. Martin A (1993) Physical Pharmacy. Lippincott Williams & Wilkins, Baltimore, Maryland
25. James KC (1986) Solubility and related properties. M. Dekker, New York
26. HT Xie GJ Wang JG Sun I Tucker XC Zhao YY Xie H Li XL Jiang R Wang MJ Xu W Wang 2005 High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies J Chromatogr B Analyt Technol Biomed Life Sci 818 167 173
27. T Akao M Kanaoka K Kobashi 1998 Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay Biol Pharm Bull 21 245 249
28. IB Paek Y Moon J Kim HY Ji SA Kim DH Sohn JB Kim HS Lee 2006 Pharmacokinetics of a ginseng saponin metabolite compound K in rats Biopharm Drug Dispos 27 39 45
29. H Hasegawa KS Lee T Nagaoka Y Tezuka M Uchiyama S Kadota I Saiki 2000 Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters Biol Pharm Bull 23 298 304
30. T Ota M Maeda S Odashima 1991 Mechanism of action of ginsenoside Rh2: uptake and metabolism of ginsenoside Rh2 by cultured B16 melanoma cells J Pharm Sci 80 1141 1146
31. HT Xie GJ Wang M Chen XL Jiang H Li H Lv CR Huang R Wang M Roberts 2005 Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells Biol Pharm Bull 28 383 386
32. SE Chen RJ Sawchuk EJ Staba 1980 American ginseng. III. Pharmacokinetics of ginsenosides in the rabbit Eur J Drug Metab Pharmacokinet 5 161 168
33. AJ Saad R Domiati-Saad TR Jerrells 1993 Ethanol ingestion increases susceptibility of mice to Listeria monocytogenes Alcohol Clin Exp Res 17 75 85
34. HE Kim JH Oh SK Lee YJ Oh 1999 Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent pathway Life Sci 65 PL33 PL40
35. XF Fei BX Wang S Tashiro TJ Li JS Ma T Ikejima 2002 Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells Acta Pharmacol Sin 23 315 322
36. JA Park KY Lee YJ Oh KW Kim SK Lee 1997 Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis Cancer Lett 121 73 81
37. YS Kim SH Jin YH Lee JD Park SI Kim 2000 Differential expression of protein kinase C subtypes during ginsenoside Rh2-induced apoptosis in SK-N-BE(2) and C6Bu-1 cells Arch Pharm Res 23 518 524